[go: up one dir, main page]

EA200300807A1 - Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы - Google Patents

Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы

Info

Publication number
EA200300807A1
EA200300807A1 EA200300807A EA200300807A EA200300807A1 EA 200300807 A1 EA200300807 A1 EA 200300807A1 EA 200300807 A EA200300807 A EA 200300807A EA 200300807 A EA200300807 A EA 200300807A EA 200300807 A1 EA200300807 A1 EA 200300807A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonists
oxidase
amino acid
aspartotoxidase
treatment
Prior art date
Application number
EA200300807A
Other languages
English (en)
Other versions
EA006654B1 (ru
Inventor
Даниель Коэн
Илья Чумаков
Original Assignee
Женсет С. А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Женсет С. А. filed Critical Женсет С. А.
Publication of EA200300807A1 publication Critical patent/EA200300807A1/ru
Publication of EA006654B1 publication Critical patent/EA006654B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Раскрыты соединения, которые являются антагонистами оксидазы D-аминокислот и D-аспартатоксидазы, способы лечения нарушений ЦНС, в том числе биполярного нарушения, психоза и шизофрении с использованием соединений и фармацевтически приемлемых композиций, которые содержат эти антагонисты.Отчет о международном поиске был опубликован 2004.02.26.
EA200300807A 2001-01-16 2002-01-15 Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы EA006654B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26188301P 2001-01-16 2001-01-16
US30544501P 2001-07-13 2001-07-13
US34521101P 2001-10-22 2001-10-22
US33388101P 2001-11-19 2001-11-19
PCT/IB2002/001262 WO2002066672A2 (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists

Publications (2)

Publication Number Publication Date
EA200300807A1 true EA200300807A1 (ru) 2004-08-26
EA006654B1 EA006654B1 (ru) 2006-02-24

Family

ID=27500728

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300807A EA006654B1 (ru) 2001-01-16 2002-01-15 Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы

Country Status (11)

Country Link
EP (1) EP1412515A2 (ru)
JP (1) JP2004537275A (ru)
KR (1) KR20030066813A (ru)
CN (1) CN1568370A (ru)
AU (1) AU2002247939B2 (ru)
BR (1) BR0206495A (ru)
CA (1) CA2433866A1 (ru)
EA (1) EA006654B1 (ru)
IL (1) IL156865A0 (ru)
MX (1) MXPA03006321A (ru)
WO (1) WO2002066672A2 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916850B2 (en) 2001-05-03 2005-07-12 Galileo Pharmaceuticals, Inc. Pyruvate derivatives
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
IL162481A0 (en) * 2001-12-12 2005-11-20 Genset Sa Method and use of determining genotype
EP1495041A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc INHIBITION OF GENE EXPRESSION OF G72 AND D-AMINO ACID OXIDASE (DAAO) INDUCED BY RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACID (NASI)
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
BRPI0418244A (pt) 2003-12-29 2007-04-17 Sepracor Inc composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
CA2636042C (en) * 2006-01-09 2014-10-14 Oklahoma Medical Research Foundation Lanthionine-related compounds for the treatment of inflammatory diseases
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
GB2456390A (en) * 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
JP5675650B2 (ja) 2009-01-20 2015-02-25 ロサンゼルス バイオメディカル リサーチ インスティテュート アットハーバー− ユーシーエルエー メディカル センター 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
JP4462382B1 (ja) * 2009-04-23 2010-05-12 学校法人北里研究所 Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤
WO2012135119A1 (en) * 2011-03-25 2012-10-04 Genomind, Llc Biomarker-based detection and treatment of neurodegenerative depression
AU2013202595B2 (en) 2012-03-30 2016-04-21 Biogen Ma Inc. Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
JP6958922B2 (ja) 2016-06-13 2021-11-02 シニュークス インターナショナル（タイワン）コーポレイション 安息香酸ナトリウムの共結晶及びその使用
MX2018015463A (es) 2016-06-13 2019-05-27 Syneurx Int Taiwan Corp Co-cristales de benzoato de litio y sus usos.
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
CN108504752B (zh) * 2018-06-26 2021-05-11 华中农业大学 一种与母猪繁殖性状关联的分子标记及应用
CN111909907B (zh) * 2020-07-08 2022-05-24 浙江工业大学 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
JP2002539845A (ja) * 1999-03-30 2002-11-26 ジェンセット 精神分裂病関連遺伝子、タンパク質およびバイアレリックマーカー
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol

Also Published As

Publication number Publication date
EP1412515A2 (en) 2004-04-28
EA006654B1 (ru) 2006-02-24
CN1568370A (zh) 2005-01-19
AU2002247939B9 (en) 2002-09-04
AU2002247939B2 (en) 2007-01-25
BR0206495A (pt) 2006-01-24
CA2433866A1 (en) 2002-08-29
MXPA03006321A (es) 2003-10-06
WO2002066672A2 (en) 2002-08-29
JP2004537275A (ja) 2004-12-16
IL156865A0 (en) 2004-02-08
KR20030066813A (ko) 2003-08-09
WO2002066672A3 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
EA200300807A1 (ru) Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
IS2564B (is) Heterófjölhringjaefnasambönd og notkun þeirra sem metabótrópísk mótlyf gegn glútamat viðtökum
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
DE69837809D1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
BG102999A (bg) Нови 2,3 дизаместени-4(3н)-хиназолинони
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
DE69425267D1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
ATE175198T1 (de) N-acylierte trizyklische azaheteroringe verwendbar als vasopressin-antagonisten
MXPA02012681A (es) Compuestos de sales de ditosilato de quinazolina.
NO20022655L (no) <Beta>-2-adrenerge reseptoragonister
ATE277072T1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
MY124786A (en) Bis-arylsulfones
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
EA200000741A1 (ru) Новые производные дигидроксигексановой кислоты
GB0322510D0 (en) Novel compounds
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
DE60327709D1 (de) Fusionierte cycloalkyl amid- und carbonsäure-derivate und deren therapeutische verwendung zur behandlung von u.a. epilepsie
NO176097C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte cykloheksener
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
PT804186E (pt) Compostos alcaloides diterpenicos de indole

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU